Cargando…

Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England

INTRODUCTION: Fluenz Tetra is an intranasal quadrivalent live attenuated influenza vaccine (QLAIV) and is recommended as the vaccine of choice for children in the 2014/2015 influenza season vaccination programme in the UK. OBJECTIVE: The primary objective of the study was to estimate the crude incid...

Descripción completa

Detalles Bibliográficos
Autores principales:	McNaughton, Rhian, Lynn, Elizabeth, Osborne, Vicki, Coughtrie, Abigail, Layton, Deborah, Shakir, Saad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2016
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796333/ https://www.ncbi.nlm.nih.gov/pubmed/26798051 http://dx.doi.org/10.1007/s40264-015-0384-7

Ejemplares similares

An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-making
por: McNaughton, Rhian, et al.
Publicado: (2014)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
por: Thorrington, Dominic, et al.
Publicado: (2017)

Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort
por: Coughtrie, Abigail L, et al.
Publicado: (2017)

Indicators of Drug-Seeking Aberrant Behaviours: The Feasibility of Use in Observational Post-Marketing Cohort Studies for Risk Management
por: Layton, Deborah, et al.
Publicado: (2014)

Observational assessment of safety in seroquel (OASIS): a specialist cohort event monitoring (SCEM) study in England
por: Osborne, Vicki, et al.
Publicado: (2020)

Alternative Strategy for a Quadrivalent Live Attenuated Influenza Virus Vaccine
por: Wan, Zhimin, et al.
Publicado: (2018)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Postmarketing studies: can they provide a safety net for COVID-19 vaccines in the UK?
por: Dhanda, Sandeep, et al.
Publicado: (2022)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

No safety signals for GSK quadrivalent influenza vaccine
Publicado: (2022)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge
por: Hill-Batorski, Lindsay, et al.
Publicado: (2023)

Trivalent and quadrivalent influenza vaccination effectiveness in Australia and South Africa: results from a modelling study
por: Milne, George J., et al.
Publicado: (2016)

Respiratory PCR detects influenza after intranasal live-attenuated influenza vaccination
por: Lumley, S, et al.
Publicado: (2013)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model
por: Rudenko, Larisa, et al.
Publicado: (2018)

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
por: Rumi, Filippo, et al.
Publicado: (2023)

Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
por: Tisa, V., et al.
Publicado: (2016)

Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-derived Quadrivalent Influenza Vaccines in Preventing Influenza-like Illness in 2017–2018
por: Boikos, Constantina, et al.
Publicado: (2020)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

Quadrivalent influenza nanoparticle vaccines induce broad protection
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2021)

Acceptability of intranasal live attenuated influenza vaccine, influenza knowledge and vaccine intent in The Gambia
por: Armitage, Edwin P., et al.
Publicado: (2018)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

What Is the Difference Between Observed Association and Causal Association, Signals and Evidence? Examples Related to COVID-19
por: Osborne, Vicki, et al.
Publicado: (2021)

Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) — United States, 2018–19 Influenza Season
por: Grohskopf, Lisa A., et al.
Publicado: (2018)

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control
por: Ray, Riju, et al.
Publicado: (2017)

Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia
por: Jamotte, Aurélien, et al.
Publicado: (2016)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Will a Quadrivalent Vaccine Solve the Problem of Influenza B Mismatches?
por: Choi, Eun Hwa, et al.
Publicado: (2018)

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia
por: Aljunid, Syed Mohamed, et al.
Publicado: (2023)

Specialist Cohort Event Monitoring Studies: A New Study Method for Risk Management in Pharmacovigilance
por: Layton, Deborah, et al.
Publicado: (2015)

Direct and Indirect Protection with Pediatric Quadrivalent Live-Attenuated Influenza Vaccination in Europe Estimated by a Dynamic Transmission Model
por: Gerlier, Laetitia, et al.
Publicado: (2017)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
por: Krishnarajah, Girishanthy, et al.
Publicado: (2021)

The Role of the Contextual Cohort to Resolve Some Challenges and Limitations of Comparisons in Pharmacoepidemiology
por: Osborne, Vicki, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qejb0m4q31uicc0jp6htqsi5aj